Recent studies have shown that CFLAR inhibits the phosphorylation of JNK, thereby ameliorating the pathological features of NASH, such as disorders of glucolipid metabolism, oxidative stress, inflammation and liver fibrosis (Wang et al., 2017). This evidence concerns the gene MAPK8 and metabolic dysfunction-associated steatohepatitis.